The company has updated its full-year guidance to reflect slower growth in our TAS segment and the impact of the strengthening US dollar. The updated revenue guidance range of $14,885M to $14,920M represents growth of 3.3 to 3.5% on a reported basis and 3.7 to 3.9% at constant currency. Excluding approximately $600M of COVID-related revenue step down versus 2022, the guidance represents growth at constant currency of approximately 9 percent, including about 140 basis points of contribution from acquisitions. Reflecting the adjustment to revenue guidance, the company is also updating its Adjusted EBITDA guidance range to $3,560 million to $3,570 million, representing growth of 6.4 to 6.7 percent, and its Adjusted Diluted Earnings per Share guidance range to $10.16 to $10.23, flat to up 0.7 percent on a reported basis. This Adjusted Diluted Earnings per Share guidance includes the year-over-year impact of the step-up in interest rates and the increase in the UK corporate tax rate. Excluding these items, Adjusted Diluted Earnings per Share is expected to grow 11 to 12 %.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IQV:
- Wells Fargo Analysts Upgrade Veeva Systems (NYSE:VEEV) to Overweight
- Iqvia price target raised to $248 from $239 at Baird
- Iqvia price target lowered to $240 from $260 at Evercore ISI
- Agilon Health price target lowered to $20 from $21 at Evercore ISI
- Iqvia price target lowered to $229 from $250 at Mizuho